The 'transformative' Lilly drug that could top $25 billion in sales

The ‘transformative’ Lilly drug that could top $25 billion in sales

Eli LilyMounjaro’s potential anti-diabetic drug (LLY) is “risk-free and transformative,” an analyst said Thursday as he updated LLY’s stock. X UBS analyst Colin Bristow now expects Mounjaro to generate more than $25 billion in peak annual sales, about $5 billion more than his previous estimate. The Food and Drug Administration has approved Mounjaro for patients …

The ‘transformative’ Lilly drug that could top $25 billion in sales Read More »